country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P99100A

Copy Link Print Information

Visugromab (Powder)

Name: Visugromab (Powder)
Brand: MedChemExpress
SKU: HY-P99100A
Availability: PreOrder

(別名: CLT-002 (Powder))

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 2556646-63-8

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (258 KB)

Visugromab (Powder) 構造式

CAS 番号: 2556646-63-8

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体内実験
- Conjugated
- Reconsititution
- Format
- アプリケーション
化学情報
Publications (2)
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

GDF15

TGF-beta/Smad アイソフォーム固有の製品をすべて表示 :

Smad1
Smad3

TGF-β Receptor アイソフォーム固有の製品をすべて表示 :

体内実験

Visugromab (up to 100 mg/kg; per week) shows no toxicity in the pre-clinical toxicology test of cynomolgus monkeys^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG4-kappa

アプリケーション

ELISA, FACS, Functional assay

化学情報

CAS 番号 2556646-63-8
SMILES

[Visugromab (Powder)]
別名

CLT-002 (Powder)
Formulation

Please refer to the lot-specific COA for specific buffer information.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All ELISACell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Mol Cell Biochem

Senescence of endothelial cells promotes phenotypic changes in adventitial fibroblasts: possible implications for vascular aging. [Abstract]

2025 Feb;480(2):1027-1043. PMID: 38743322

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

GDF-15 protein level measured by ELISA in CM following 1h incubation with different concentrations of Visugromab (0.625-20 μg/mL). 20 μg/mL was selected as the effective neutralization concentration.

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

The quantification of EdU positive nuclei as a percentage of all nuclei for hAdv cultured in control conditions (hAdv) or in the presence of Visugromab (20 μg/ml) in culture medium. Addition of Visugromab directly to hAdv cells culture medium resulted in decreased proliferation rate of the cells.
bioRxiv

2025 Oct 23.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (258 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

参考文献

[1]. Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER)[J]. 2023.

[2]. Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637(8048):1218-1227. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Visugromab (Powder)

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- IC₅₀ & Target
- 体内実験
- Conjugated
- Reconsititution
- Format
- アプリケーション
化学情報
Publications (2)
純度とドキュメンテーション
参考文献

1/16

IgG4-kappa
1/16

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

Customer Validation
GDF-15 protein level measured by ELISA in CM following 1h incubation with different concentrations of Visugromab (0.625-20 μg/mL). 20 μg/mL was selected as the effective neutralization concentration.
1/16

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

Customer Validation
The quantification of EdU positive nuclei as a percentage of all nuclei for hAdv cultured in control conditions (hAdv) or in the presence of Visugromab (20 μg/ml) in culture medium. Addition of Visugromab directly to hAdv cells culture medium resulted in decreased proliferation rate of the cells.
1/16

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Visugromab (Powder)

MedChemExpress（MCE）の使用を引用している文献 Visugromab (Powder)

TGF-beta/Smad アイソフォーム固有の製品をすべて表示

TGF-β Receptor アイソフォーム固有の製品をすべて表示

生物活性